DA-002

Phase 3Small molecule

AApplied Biology, Inc.

DA-002 is one of 46 small molecule programs targeting Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentNot yet recruiting

TreatmentPhase 3

Not yet recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

DA-002

AApplied Biology, Inc.

Phase 3

1 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Theo-Dur

Pfizer

Preclinical

1 7

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

Not yet recruiting·AApplied Biology, Inc.·Phase 3·NCT06501924·516 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DA-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Applied Biology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AApplied Biology, Inc.

DA-002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

References

Drug Info

Quick Facts

Related News